Assessment of Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status in Breast Carcinoma Using Thin-Prep Cytology Fine Needle Aspiration Cytology FISH Experience from China

Medicine (United States)

Volumn 94, Issue 24, 2015, Pages

  Zhang, Zhihui ^a   Yuan, Peng ^a   Guo, Huiqin ^a   Zhao, Linlin ^a   Ying, Jianming ^a   Wang, Mingrong ^a   Zhao, Huan ^a   Pan, Qinjing ^a   Xu, Binghe ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P53; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CYTOLOGY; DIAGNOSTIC ACCURACY; DUCTAL BREAST CARCINOMA IN SITU; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INVASIVE CARCINOMA; KIDNEY BIOPSY; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDULLARY CARCINOMA; MINIMALLY INVASIVE PROCEDURE; MOLECULAR DIAGNOSIS; NEEDLE BIOPSY; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; BIOSYNTHESIS; BREAST NEOPLASMS; CHINA; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CHINA; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SENSITIVITY AND SPECIFICITY;

EID: 84941338651     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000981     Document Type: Article

References (36)

1. Kontzoglou K, Moulakakis KG, Konofaos P, et al. The role of liquid-based cytology in the investigation of breast lesions using fine-needle aspiration: a cytohistopathological evaluation. J Surg Oncol. 2005;89:75–78.
2. Hoda RS. Non-gynecologic cytology on liquid-based preparations: a morphologic review of facts and artifacts. Diagn Cytopathol. 2007;35:621–634.
3. Fadda G, Rossi ED, Mulè A, et al. Diagnostic efficacy of immunocytochemistry on fine needle aspiration biopsies processed by thin-layer cytology. Acta Cytol. 2006;50:129–135.
4. Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23:7721–7735.
5. Osborne CK, Schiff R, Arpino G, et al. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005;14:458–465.
6. Veronesi U, Boyle P, Goldhirsch A, et al. Breast cancer. Lancet. 2005;365:1727–1741.
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672.
8. Goldstein NS, Ferkowicz M, Odish E, et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003;120:86–92.
9. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134:907–922.
10. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013;31:3997–4013.
11. Briffod M, Le Doussal V, Spyratos F. Immunohistochemical determination of hormonal receptors on cell-blocks from fine-needle cytopunctures of breast carcinoma. Bull Cancer. 2001;88:1028–1035.
12. Veneti S, Daskalopoulou D, Zervoudis S, et al. Liquid-based cytology in breast fine needle aspiration. Comparison with the conventional smear. Acta Cytol. 2003;47:188–192.
13. Idirisinghe PK, Thike AA, Cheok PY, et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol. 2010;133:416–429.
14. Zhang ZH, Zhao DB, Zhao LL, et al. The value of thin-layer cytology in intraoperative fine-needle aspiration biopsy of pancreatic cancer. Zhonghua Zhong Liu Za Zhi. 2008;30:476–479.
15. Tabbara SO, Sidawy MK, Frost AR, et al. The stability of estrogen and progesterone receptor expression on breast carcinoma cells stored as PreservCyt suspensions and as ThinPrep slides. Cancer. 1998;84:355–360.
16. Sauer T, Ebeltoft K, Pedersen MK, et al. Liquid based material from fine needle aspirates from breast carcinomas offers the possibility of long-time storage without significant loss of immunoreactivity of estrogen and progesterone receptors. Cytojournal. 2010;7:24.
17. Konofaos P, Kontzoglou K, Georgoulakis J, et al. The role of ThinPrep cytology in the evaluation of estrogen and progesterone receptor content of breast tumors. Surg Oncol. 2006;15:257–266.
18. Nishimura R, Aogi K, Yamamoto T, et al. Usefulness of liquid-based cytology in hormone receptor analysis of breast cancer specimens. Virchows Arch. 2011;458:153–158.
19. Beatty BG, Bryant R, Wang W, et al. HER2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol. 2004;122:246–255.
20. Bofin AM, Ytterhus B, Martin C, et al. Detection and quantitation of HER2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol. 2004;122:110–119.
21. Lee JW, Noh WC, Kim MS, et al. Availability of fine needle aspirates for the assessment of HER2 gene amplification in invasive breast cancer patients. Korean J Lab Med. 2008;28:392–399.
22. Gu M, Ghafari S, Zhao M, et al. Fluorescence in situ hybridization for HER2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens. Acta Cytol. 2005;49:471–476.
23. Kapila K, Al-Awadhi S, Francis I. HER2 neu (Cerb-B2) expression in fine needle aspiration samples of breast carcinoma: a pilot study comparing FISH, CISH and immunocytochemistry. J Cytol. 2011;28:54–56.
24. Pegolo E, Machin P, Riosa F, et al. Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma correlation with histologic sections determination. Cancer Cytopathol. 2012;120:196–205.
25. Domanski AM, Monsef N, Domanski HA, et al. Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients. Cytopathology. 2013;24:21–25.
26. Durgapal P, Mathur SR, Kalamuddin M, et al. Assessment of Her-2/ neu status using immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology smears: experience from a tertiary care centre in India. Diagn Cytopathol. 2014;42:726–731.
27. Moriki T, Takahashi T, Ueta S, et al. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls. Diagn Cytopathol. 2004;30:251–256.
28. De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005;11:4741–4748.
29. Tan YO, Han SW, Lu YS, et al. The prevalence and assessment of ErbB2-positive breast cancer in Asia. Cancer. 2010;116:5348–5357.
30. Bueno Angela SP, Viero RM, Soares CT, et al. Fine needle aspirate cell blocks are reliable for detection of hormone receptors and HER2 by immunohistochemistry in breast carcinoma. Cytopathology. 2013;24:26–32.
31. Kinsella MD, Birdsong GG, Siddiqui MT, et al. Detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples. Diagn Cytopathol. 2013;41:192–198.
32. Sumiyoshi K, Shibayama Y, Akashi S, et al. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections? Oncol Rep. 2006;15:803–808.
33. Bedard YC, Pollett AF, Leung SW, et al. Assessment of thin-layer breast aspirates for immunocytochemical evaluation of HER2 status. Acta Cytol. 2003;47:979–984.
34. Halimi M, Aghbali AA, Tabrizi AD, et al. Expression of epidermal growth factor receptor tyrosine kinase family in fine needle aspiration and permanent specimens of invasive lobular and ductal breast cancers. Pak J Biol Sci. 2011;14:584–589.
35. Kuo SJ, Wang BB, Chang CS, et al. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER2/neu status in Taiwanese breast cancer patients. Taiwan J Obstet Gynecol. 2007;46:146–151.
36. Murthy SS, Sandhya DG, Ahmed F, et al. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center. Indian J Pathol Microbiol. 2011;54:532–538.